SAGA Diagnostics drives the development of liquid biopsy technology for ultra-sensitive cancers

foreign media learned that recently, SAGA Diagnostics announced the completion of $4.1 million round A financing. This round of investments is led by Hadean Ventures, followed by the Fårö Capital and gunnar Nilsson Cancer Foundation. The funds will be used to accelerate the development and development of SAGA kits and to conduct forward-looking clinical studies to advance the development of liquid biopsy technology for ultra-sensitive cancers.

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that provides molecular genetic testing services for tissue biopsies and non-invasive "liquid living tissue examinations". SAGA Diagnostics provides testing services for pharmaceutical companies, scientists and biomedical laboratories, stratization of patient populations to more accurately monitor patient response. The company uses proprietary technology to analyze circulating tumor DNA, and SAGA technology uses unique ultra-sensitivity to detect patients. SAGA technology straties, diagnoses, and monitors cancer treatment responses to identify disease recurrences.

, chief executive of SAGA Diagnostics, said: "We are delighted that Hadean Ventures, the leading life sciences venture capital institution in Northern Europe, has invested in us. We look forward to working with the Hadean team to create a new era in cancer diagnosis and help cancer patients. Innrid Teigland Akay

of Hadean Ventures, a company with world-class advanced technology in Northern Europe. We are proud to work with SAGA and look forward to further developing more with our team to address the global challenges of healthcare. Walter Stockinger

managing partner at Hadean Ventures and a new board member of SAGA, said: "We believe liquid biopsy will increasingly become an important technology for cancer treatment in the future. SAGA's unique technology has made it stand out in the field of cancer detection and treatment, and has successfully attracted us. On

15, 2018, SAGA Diagnostics received EUR 1 million in seed round financing. To date, the company's total financing amounted to $5.5 million.
about Hadean Ventures

is a life sciences company that invests in projects across Europe, with a particular focus on the Nordic region. Hadean Ventures has offices in Oslo and Stockholm and works with world-class academic institutions and start-up centres in the region.
about Fårö Capital Fårö is an Argentine company with over 10 years of experience in the development and operation of integrated projects in the ad-enterprise sector. With a wealth of expertise in a combination of ad agricultural enterprises, Fårö is committed to the efficient use of land resources in intensive production in the short and medium term.
gunnar Nilsson Cancer FoundationGunnar Nilsson was founded in 1979 and has invested dozens of projects in cancer research and treatment programs. Its founder, who underwent intensive radiotherapy for testicular cancer, set out to set up the Gunnar Nilsson Cancer Foundation in the final stages of his life. (Arterial mesh)